-transparent.png){kind=logo}
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 1992
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10(-12) M to 5 x 10(-14) M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
Related Publications
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
April 1995,
Blood,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
January 1998,
Journal of drug targeting,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
September 1998,
British journal of haematology,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
October 1994,
Hepatology (Baltimore, Md.),
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
October 1989,
Blood,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
June 2002,
Clinical cancer research : an official journal of the American Association for Cancer Research,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
September 1992,
British journal of haematology,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
June 2016,
Toxins,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
July 1992,
The American journal of pathology,
P L Tazzari, and
A Bolognesi, and
D de Totero, and
B Falini, and
R M Lemoli, and
M R Soria, and
S Pileri, and
M Gobbi, and
H Stein, and
L Flenghi
December 1995,
British journal of cancer,
